Considering these ratios, the Alzheimer’s disease network associates were as a group more oncogenic than the associates of BCL-2, considered to be a benchmark oncogene and this result is counterintuitive, considering the degenerative character of the disease. This evidence concerns the gene BCL2 and early-onset autosomal dominant Alzheimer disease.